Hints and tips:
...As chief executive and later chair of Glaxo in the 1980s, Girolami, who has died aged 97, transformed a minor player in the pharmaceutical industry into a world leader....
...In second place, with five promotions and demotions, is Hikma Pharmaceuticals....
...Glaxo first bought Wellcome in 1995 and then SmithKline Beecham in 2000, becoming GSK. Glencore acquired Xstrata in 2013....
...And because the definition of “tech” included pharmaceuticals, media, telecoms and miscellaneous, the LSE found 181 stocks worthy of inclusion from day one....
...He pointed to the merger, almost 20 years ago, of Glaxo Wellcome with SmithKline Beecham, creating global behemoth GSK, which demonstrated that “the process was not as easily ‘industrialisable’ as people...
...In the world of patented pharmaceuticals, “first-mover advantage” isn’t everything. Glaxo’s Zantac ulcer treatment proved as much in the 1980s....
...combined with SmithKline Beecham to create GSK....
...A veteran of the pharmaceuticals industry, he experienced a big merger while working for SmithKline Beecham when it combined with Glaxo Wellcome in 2000....
...That was what happened in the last big round of consolidation, around the turn of the millennium, through Glaxo Wellcome’s merger with SmithKline Beecham and Pfizer’s with Warner-Lambert and Wyeth....
...Megamergers such as Pfizer’s $90bn takeover of Warner-Lambert in 1999 and SmithKline’s $72bn merger with Glaxo had struggled to produce growth....
...I was an investor in Glaxo Wellcome and SmithKline Beecham through most of the 1990s, before their merger into one entity....
...It also set in train a process in which the Wellcome company was later bought by Glaxo, becoming part of a multinational that expanded further to become GlaxoSmithKline....
...Others are following, with Glaxo SmithKline and Merck among the companies testing rival vaccines....
...Glaxo’s phase one and two drugs are valued at just $10bn, about a 10th of its current market value....
...Mr Garnier led SmithKline before its 2001 merger with Glaxo Wellcome....
...As Glaxo Wellcome chief, he oversaw its merger with SmithKline Beecham in 2000, and stepped down in 2002 at the age of 60....
...His Convergence Pharmaceuticals company, in which GSK has invested and transferred scientists, is just the latest in a series of profitable start-ups....
...He was also finance director at BG Group and chief financial officer at SmithKline Beecham, which merged with Glaxo Wellcome in 2000 to createGlaxoSmithKline....
...Stocks such as BP, Shell and GlaxoSmithKline saw inflows as fund managers sought income elsewhere. But a wobble in just one of these companies causes a headache for funds....
...Glaxo has held shares in Quest since 1999, when Glaxo sold its clinical laboratories business to the New Jersey-based group. In 1999, Smithkline Beecham held a 29 per cent stake in the group....
...Sector peer Shire drifted 0.4 per cent to £10.27 on talk that potential predator Teva Pharmaceuticals would instead turn its intentions on US antiviral maker ViroPharma....
...GSK, formed by a merger between Glaxo Wellcome and SmithKline Beecham in 2000, knows size alone is no cure-all....
...The same person said Mr Murdoch would remain focused on News Corporation’s European and Asian businesses....
...In a further cost, the board is likely to have to at least match the current package of Mr Le Fur’s successor, Chris Viehbacher from Glaxo-SmithKline, who earned $800,000 last year, with a £2.5m retention...
...While a few large companies, including Novartis and Merck, retained their libraries, most others sold them off, including GlaxoSmithKline, which spun out some of the assets that were merged into MerLion...
International Edition